PTHS PTHS Research and Development operations — Net loss

Other segment segments

Similar metrics at other companies

COGTResearch And Development Software Facilities And Other Strategic Support — Operating Income

$5.73M+29.6%

RNTXClinical Operation Activities — Research And Development Expense

$1.96M+191%

OKURClinical Research — Net Income Loss

-$15.62M+8.1%

MLYSResearch and development expenses

$4.59M-52.5%

GERNResearch and clinical expenses — R&D

$13M-5.1%

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

Questions, answered.

What is PTHS's research and development operations — net loss?

PTHS (PTHS) reported research and development operations — net loss of $55K in Q1 2026.

How has PTHS's research and development operations — net loss changed year-over-year?

PTHS's research and development operations — net loss increased by 102.8% year-over-year, from -$1.97M to $55K.

What does research and development operations — net loss mean?

Measures the net financial deficit incurred by the research and development segment after accounting for all associated operating expenses. This reflects the capital intensity of the company's clinical trials and drug discovery efforts. A narrowing loss may indicate improved operational efficiency or the achievement of specific development milestones.